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November 20111542 AbstractsVeinMapping Prior to Endovenous Catheter Ablation of Great Saphe-
nous Vein Predicts Risk of Endovenous Heat-Induced Thrombus
Formation
Judith C. Lin, MD, Edward L. Peterson, PhD, Jennifer J. Smith, MD,
Melinda L. Rivera, Mitchell R. Weaver, MD, Division of Vascular Surgery,
Henry Ford Hospital, Detroit, Mich
Objectives: The incidence of endovenous heat-induced thrombus
(EHIT) and deep vein thrombosis (DVT) after endovenous laser treatment
(EVLT) or radiofrequency ablation (VNUS) of truncal vein is low. However,
the consequence may be lethal. We investigate the value of vein mapping prior
to vein ablation for predicting the risk of thrombus formation.
Methods: 355 consecutive vein mappings were prospectively collected
and analyzed. Excluded were 29 patients who did not complete the EVLT or
VNUS procedure. All symptomatic patients underwent venous duplex ul-
trasound to assess for valvular incompetence. Preoperative venous reflux is
defined as0.5 second. Vein mapping of refluxing truncal veins was done at
least the day prior and the diameter of the great saphenous vein (GSV) or
small saphenous vein (SSV) measured. Post-operative duplex were per-
formed between 5-7 days after the procedure. Bivariate analysis of indepen-
dent variables by outcomes was performed using Student’s t-test for contin-
uous variable, chi-square test for categorical variables, and logistic regression
to estimate the odds ratio (OR). Multivariate logistic models were used to
adjust for diameter and refluxing vein.
Results: Among the 355 studies in 330 patients, the average age of the
patients was 55.2 years; 96 male (29.1%) and 231 female (70.9%); 312 were
GSV (95.7%) and 14 SSV (4.3%); 169 right leg (51.4%) and 157 left leg
(48.2%). Among 326 veins, 169 were treated with VNUS (51.8%) and 157
EVLT (48.2%). The immediate post-procedure closure was seen in 319
veins (97.9%). Among the 312 GSV ablation procedures, 10 (3.2%) devel-
oped EHIT or DVT.When comparing the group of patients who developed
EHIT versus no EHIT, the mean GSV diameter was 12.75  5.76 mm
versus 8.5  3.44 mm (OR 1.23, P  .001), the presence of valvular
incompetence at the saphenofemoral junction was 8.33% vs. 0.44% (OR
20.64, p.001), and 3.09% in VNUS vs. 2% in EVLT (OR 0.64, P  .54)
Conclusions: Patients with valvular insufficiency of the saphenofemo-
ral junction and a large proximal GSV diameter had significantly higher risk
of developing heat-induced thrombus formation after endovenous catheter
ablation. There was no difference in the occurrence of EHIT with EVLT or
VNUS procedures in our series.
Bovine Pericardial Patch Repair in Infected Fields
WilliamMcMillan,MD,ChantelHile,MD,ChristopherLeville,MD,Minneapolis
Vascular Physicians, Plymouth,Minn
Objectives: Bovine pericardial patches (BPP) are frequently used for
arterial reconstruction, but little data exists regarding their ability to resist
infection. We hypothesize that BPP would provide a reasonable alternative
to autologous vein patches in infected fields.
Methods:Weused BPP (Synoviousmedical) to repair 51 arteriotomies
(25 brachial, 23 femoral, 3 popliteal) in 48 consecutive patients (mean age
68, 65% men, 75% diabetic, 67% dialysis dependent) undergoing removal of
infected (33 gram positive, 3 gm negative and 8 mixed flora and 4 culture
negative) PTFE grafts ( 35 AV graft, 9 femoral-distal bypass, 4 femoral patch
angioplasty), between 1/2007 and 1/2011. Patients were followed retro-
spectively and outcomes including death, rupture, secondary reconstruction
and infection were recorded.
Results:Over a mean follow up of 2.1 years (range 3-48months) 50 of
51 patches remained in place without evidence of recurrent infection,
rupture or revision. One patient had acute rupture of a popliteal arteriotomy
1 week post repair and had subsequent ligation and above knee amputation.
Eight of the 48 patients died from unrelated causes during follow up. (3
withdrew from dialysis, 3 MI, 2 unkown)
Conclusions: Bovine pericardial patches provide a durable alternative
to saphenous vein for arterial reconstruction following removal of infected
arterial grafts.
Aberrant Subclavian Artery: Presentation and Outcomes
Borzoo Farhang, Nitin Garg, William M. Stone, MD, Joseph J. Ricotta,
MD, Thomas C. Bower, MD, Mayo Clinic, Rochester, Minn
Objectives: Aberrant subclavian artery (ASA) is one of most frequent
aortic arch anomalies. Many authors recommend treatment of symptomatic
or aneurysmal aberrant subclavian arteries, but most of these recommenda-
tions are based on small case series or anecdotal experience. Natural history
of this anomaly is not well defined. Our aim was to review long term
outcomes in patients with this anomaly.
Methods: A retrospective review of all adult patients seen at Mayo Clinic
between1997and2011withadiagnosisofASAwasperformedafter approval from
our institutional review board. Demographic factors and outcome data was col-
lected and analyzed. All patients were diagnosed based on imaging studies.Results: There were 446 patients with diagnosis of Asa and mean age
at diagnosis was 54.7 years (range 1month- 93 years). There were 102berrant left and 344 aberrant right subclavian arteries in 164 male and 284
emale patients. There were more female patients than male with right ASA
2:1) versus similar distribution for left ASA (1.25:1). Forty five (10%)
atients were symptomatic, the most common symptoms being dysphagia
nd/or respiratory. These were presumed from compression, althoughmost
atients noted to have esophageal compression on radiographic study had
o dysphagia. Forty two patients (9.4%) underwent surgical intervention for
SA, all were symptomatic or had aneurysmal degeneration. No patient
resented urgently, except one with acute upper extremity ischemia in
onjunction with aortic and subclavian dissection and underlying right Asa.
ean follow up duration was 6.3 years (range 0-70 years). None of the
atients followed conservatively developed any complications related to the
SA.
Conclusions: Aberrant subclavian artery is a benign anomaly and has
o significant long term consequences. Intervention is recommended in
ymptomatic patients, in whom other causes for symptoms have been ruled
ut. Multiple surgical options should be tailored patient specific problems.
utologous Bone Marrow Mononuclear Cell Therapy Produces Dura-
le Benefits in Limb Salvage at Five Years Post-Treatment
ndrea L. Jester, MD, Raghu L. Motaganahalli, MD, Brian M. Rapp, MD,
eorge A. Akingba, MD, Michael C. Dalsing, MD, Michael G. Wilson,
ndres Fajardo, MD, Michael P. Murphy, MD, Division of Vascular Sur-
ery, IU School of Medicine, Indianapolis, Ind
Objectives: We have previously demonstrated that autologous bone
arrow mononuclear cell (ABMNC) therapy improves measures of limb
erfusion, rest pain, wound healing, and amputation free survival (AFS) at
ne year in patients with critical limb ischemia (CLI). Long term durability
f ABMNC therapy for critical limb ischemia (CLI) remains unknown. The
bjective of this current study is to evaluate long term clinical outcomes five
ears after treatment.
Methods:Data were retrospectively gathered from a database and via a
urvey sent to patients with CLI who had previously underwent intra-
uscular transplantation of ABMNCs in the most symptomatic limb. AFS,
reedom from major amputation, and freedom from major adverse limb
vents (MALE) were calculated using the product-limit estimate. The
ncidence of cardiac, malignant and other medical events during the time
rom treatment to follow-up were tabulated.
Results: Twenty-one of the 24 (87.5%) patients who completed the
nitial one year Phase I trial responded to a detailed questionnaire Interval
rom initial treatment was 188.2 12.3 weeks, range:129- 278). At five
ears AFS was 74% (95% CI, 0.53-0.86; P  .05) (Fig 1), freedom from
ajor amputation was 78% (95% CI, 0.57-0.89; P  .05) (Fig 2) and
reedom fromMALEwas 65 % (95% CI, 0.45- 0.79; P .05) (Fig 3). Three
atients (14.2%) had major cardiac events. There were no incidences of
alignancies or diagnoses of proliferative retinopathy. Fifteen patients
71.4%) report continued improvement in pain-free walking. Nineteen
90.4%) patients felt that the study was of significant medical value and
ould participate again.
Conclusions:ABMNC therapy provides long term freedom fromAFS,
ajor amputation, and MALE that are comparable to surgical and endovas-
ular interventions for CLI. Furthermore this study eliminates the concerns
or tumor genesis and proliferative retinopathy associated with angiogenic
herapies.Fig 1.
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Volume 54, Number 5 Abstracts 1543Do Patients With Hostile Necks Have an Increased Rate of Restenosis
After CAS?
Francis J. Caputo, Jeffrey Jim, MD, Raghuveer Vallabhaneni, MD, Brian
Rubin, MD, Patrick Geraghty, MD, John Curci, MD, Kathleen Raman,
MD, Gregorio Sicard, MD, Luis Sanchez, MD, Section of Vascular Surgery,
Washington University in St. Louis, St. Louis, Mo
Objectives: The purpose of this study is to review a single institution’s
experience of carotid artery angioplasty and stenting (CAS) and re-interven-
tion rates.
Methods: A retrospective analysis of patients that underwent CAS at a
university medical center was performed over an 8-year period from August
2003 to August 2011. Data analysis included patient demographics, opera-
tive details, radiological information and postoperative outcomes.
Results: 317 CAS were performed during the study period. The mean
age of the cohort was 73.6 (range 41-94) years and 205 (64%) procedures
were performed in males. Degree of stenosis was 80% in 263 (83%)
patients and 143 (45%) had symptomatic disease. 145 (46%) of the patients
had a hostile neck (previous neck surgery and/or radiation therapy), 17
(5.3%) had a high anatomic lesion, and the remaining were considered
medically unfit for surgery. 303(96%) patients have 30-day follow-up with a
total mean follow-up of 21.8 (range 1-85) months. Restenosis of80% was
found in 21 patients (6.6%) with a mean time to restenosis of 14.7 months.
For patients with restenosis, 3 patients had an occlusion of their stents and
13 (61.9%) patients had a re-intervention of either balloon angioplasty or
CAS and the remaining were observed. Of those patients who underwent
re-intervention, 3 (14%) were due to symptomatic disease and the remaining
were treated at the physician’s discretion. Patients with a hostile neck had a
significantly higher restenosis rate of 12.5% versus those with de-novo
Fig 2.
Fig 3.lesions had a restenosis rate of 3.6% (p0.05). For the entire cohort, 30-day
rates of stroke, myocardial infarction (MI) and death was 1.6%, 1.3% and
t
c.9%, respectively. The combined 30-day stroke/death rate was 3.5%. At a
ean follow-up of 21.8 (range 1-85) months the stroke and mortality rates
ere 2.5% and 14.5%.
Conclusions: CAS can be performed safely with good 30-day out-
omes and a low incidence of stroke at two years. Restenosis rates are
ignificantly higher in patients with “hostile” necks. However, these were
ften amenable to endovascular re-intervention.
ong-Term Persistent Type 2 Endoleak Following Endovascular Ab-
ominal Aortic Aneurysm
oung Erben, MD,1 Manju Kalra, MD,1 Joseph J. Ricotta, MD,1,2 Michael
. McKusick, MD,1 Thomas C. Bower, MD,1 Gustavo S. Oderich, MD,1
udra A. Duncan, MD,1 Peter Gloviczki, MD,1 1Mayo Clinic, Rochester,
inn; 2Division of Vascular Surgery and Endovascular Therapy, Emory
niversity School of Medicine, Atlanta, Ga.
Objective:Management of type 2 endoleak (T2E) following endovas-
ular abdominal aortic aneurysm repair (EVAR) has evolved over the last
ecade to observation and selective intervention. The aim of this study was
o evaluate long-term outcomes in patients with T2E.
Methods: Data from 779 patients who underwent EVAR over a
0-year period from 1999 to 2009 were analyzed for incidence and long-
erm outcomes of T2E. Clinical records and CT angiography studies per-
ormed within 6 months following EVAR and at least annually thereafter
ere assessed.
Results: 159 patients (20.4%) were identified with a T2E over a mean
ollow-up of 37.3 months (range: 6 to 121 months). Patients were classified
ccording to the time of occurrence of their T2E post-EVAR: early (0-6
onths with resolution thereafter. n38, 23.9%), late (first noticed 24
onths, n20, 12.6%) and persistent (present at all times, n101, 63.5%).
he average sac size change was: early1.36  11.15mm, persistent0.16
6.66mm and late0.65  6.43mm. There were no aneurysm related
eaths; 73 patients died from unrelated causes during follow-up. Sixty-three
atients underwent endovascular intervention to treat the T2E: 11, 43 and
in the early, persistent and late groups, respectively. Prior to 2005
ntervention for T2E was aggressive, but subsequent to this an observational
pproach was adopted. Mean sac diameter change in patients undergoing
ntervention prior to 2005 was -0.19  9.14mm and subsequent to 2005
as 0.69  7.51mm. Fifteen (24%) patients underwent 1 intervention.
here were two complications: one sigmoid ischemia requiring colectomy
nd one psoas infarction. Using aWeibull analysis, the estimated survival free
f endoleak after an intervention at 1 and 2 years was 40% and 30%
espectively. However, further sac growth at 1 and 2 years occurred only in
5% and 42% respectively. Two patients underwent conversion to open
epair, one for contained rupture.
Conclusions: In-spite of adopting an observational policy towards
2E nearly half of all patients with persistent and late onset endoleaks
equired intervention for enlarging sac size over time. Although success at
ontrolling the endoleak was low with endovascular intervention, subse-
uent sac growth was halted in the majority. Close surveillance of patients
ith T2E is still recommended.
he Effect of Cancer on Percutaneous Intervention for Infrainguinal
eripheral Artery Disease: Are Patency Rates Impacted?
atherine A. Gallagher, MD, Andrew J. Meltzer, MD, Sikandar Khan, MD,
eid A. Ravin, Peter Connelly, MD, Darren B. Schneider, MD, James F.
cKinsey, MD, Rajeev Dayal, MD, Vascular Surgery, Weill Cornell/Co-
umbia University Medical Center, New York, NY
Introduction: It has been hypothesized that the hypercoagulable state
ssociated with malignancy results in decreased patency after peripheral
rterial endovascular intervention. We aimed to determine the long-term
utcomes of cancer patients undergoing percutaneous interventions for
AD.
Methods:A prospective database identified patients with a diagnosis of
ancer who subsequently underwent percutaneous infrainguinal arterial
nterventions from 2004-2009. Patient demographics, medical co-morbid-
ties, procedural details, and outcomes were reviewed by a dedicated research
eam. Patients were followed clinically and by duplex ultrasound at 6 month
ntervals. Kaplan-Meier survival analysis and Cox proportional hazards
odel were performed.
Results: Of 1220 patients undergoing peripheral endovascular inter-
ention, 174 (14%) were identified as having a diagnosis of malignancy.
hese patients were compared to controls with regard to smoking history
51 %vs.58%;p.012), end stage renal disease(5%vs 10%;p0.016), and
iabetes(49%vs 59%;p0.016). Primary patency rates for the cancer patients
nd controls were compared at 3 years post-intervention (50.5%vs.41.9%;
0.007). To determine if cancer is an independent risk factor for poor
atency, a multiple regression analysis was performed, controlling for diabe-
es, renal failure, smoking history, and indication for intervention (claudica-
ion or critical limb ischemia) to compare patency rates in cancer patients to
ontrols (p.215). (Table 1)
